Qualifying notice for Tepadina

Qualifying notice for Tepadina This Notice of Compliance with Conditions-Qualifying Notice (NOC/c-QN) is to advise you that information submitted in support of the New Drug Submission for Tepadina (thiotepa), control number 168816, for the indication in combination with other chemotherapeutic products as part of a high-dose chemotherapy (HDCT) consolidation regimen followed by autologous stem cell transplantation (ASCT) for adult patients with central nervous system (CNS) lymphoma, qualifies to be considered for authorization under the Notice of Compliance with Conditions (NOC/c) Policy. 2023-11-01 Health Canada open-ouvert@tbs-sct.gc.ca Health and Safetyqualifying noticeTepadinanotice-of-compliance with conditions-qualifying noticeNOC/c-QN Qualifying notice for TepadinaHTML https://www.canada.ca/en/health-canada/services/drugs-health-products/drug-products/notice-compliance/conditions/qualifying-notice-tepadina-168816.html Qualifying notice for TepadinaHTML https://www.canada.ca/fr/sante-canada/services/medicaments-produits-sante/medicaments/avis-conformite/conditions/avis-admissibilite-tepadina-168816.html

This Notice of Compliance with Conditions-Qualifying Notice (NOC/c-QN) is to advise you that information submitted in support of the New Drug Submission for Tepadina (thiotepa), control number 168816, for the indication in combination with other chemotherapeutic products as part of a high-dose chemotherapy (HDCT) consolidation regimen followed by autologous stem cell transplantation (ASCT) for adult patients with central nervous system (CNS) lymphoma, qualifies to be considered for authorization under the Notice of Compliance with Conditions (NOC/c) Policy.

Data and Resources

Similar records